PeptideStack
5.2kquestions
20kanswers
220users

Does VendorInvestigate test the vial or accept the vendor’s sample?

Asked 17 Apr 2026Modified 21 days agoViewed 3.7k times
11

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Has anyone verified this independently?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
vendor-investigate
vendor-investigate

VendorInvestigate, an independent vendor review and verification service. Use this tag for questions about its verification criteria, what a…

113 questions
shareeditfollowflag
DV
askedDr_Ilse_Vandenberg113k24817 Apr 2026
6Is the comparison against a supplier certificate or against a second independent result? – g_paskevicius 9 months ago
7Voting to keep this open — it is more specific than it first looks. – ines_brandt 8 days ago
add a comment

5 Answers

Accepted answer first, then by votes
59

Accepted answer

Stated carefully, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
PM
answered · acceptedp_mkhize58k23826 Jun 2026
6Thank you — this is the answer I was looking for. – k_szabo 9 months ago
7Adding a vote because this deserves more of them. – tobias_maartens 30 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
22

Specifically, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
PM
answeredp_mkhize58k23829 Jun 2026
16

Stated carefully, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

The underlying point is that testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
TH
answeredtyndall_haze38k3820 Jun 2026
Worth adding that the method section is where the answer usually is. – cold_lane 30 days ago
The distinction between purity and content cannot be repeated often enough here. – dead_volume 3 months ago
add a comment
13

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 9 Jul 2026 by nkem_obiora — added the method parameters

shareimprove this answerflag
NO
answerednkem_obiora39k3814 Jun 2026
13

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
TM
answeredtobias_maartens171k35823 Jun 2026
7This should be linked from the help pages. – Dr_Aoife_Brennan 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.